Digitisation | June 28, 2022
Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Strengthens investment in channels of the future to expand patient reach
Strengthens investment in channels of the future to expand patient reach
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Cipla has reported consolidated financial results for the period ended March 31, 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
Cipla has reported consolidated financial results for the period ended September 30, 2021
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
Subscribe To Our Newsletter & Stay Updated
